Differences in cytokine levels in melanoma patients with and without redness (Brenner sign)

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1793-1796

  Mashiah, Jacob ^a,d   Brenner, Sarah ^a   Pessach, Yakov ^a   Barak, Vivianne ^b   Schachter, Jacob ^c  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d NONE   (Israel)

Author keywords

IL 6; IL 8; Melanoma; Redness

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; BRENNER TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR GROWTH;

ERYTHEMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; INTERLEUKIN-8; MELANOMA;

EID: 67650093540     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Geller AC, Swetter SM, Brooks K et al: Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 57: 555-572, 2007.
2. Mashiah J, Barnea Y, Wohl Y and Brenner S: Redness, a possible signpost for malignant melanoma. J Eur Acad Dermatol Venereol 19: 514-515, 2005. (Pubitemid 40946121)
3. Mashiah J, Wohl Y, Barnea Y, Schneebaum S, Gat A, Misonzhnik-Bedny F and Brenner S: Immunohistochemical expression of platelet growth factor and vascular endothelial factor in melanoma patients with redness (Brenner's sign) and without redness. Arch Dermatol 143: 1001-1004, 2007. (Pubitemid 47296076)
4. Brenner S and Wolf R: The "red face"- A warning sign of malignant melanoma? Acta Derm Venereol (Stockh) 72: 464, 1992.
5. Tamir E and Brenner S: A case of "red face": A clue to early detection of malignant melanoma. SkinMed Derm for Clinician 2(5): 272, 2003.
6. 2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency. J Immunol 163: 6155-6163, 1999.
7. Strieter RM: Chemokines: Not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2: 285-286, 2001. (Pubitemid 33706336)
8. Govindarajan B, Sligh JE, Vincent BJ et al: Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117: 719-729, 2007. (Pubitemid 46348530)
9. Fidler U: Angiogenesis and cancer metastasis. Cancer J Suppl 2: S134-141, 2000.
10. Bar-Eli M: Role of interleukin 8 in tumor growth and metastasis of human melanoma. Pathology 67: 12-18, 1999. (Pubitemid 29037606)
11. Ugurel, S, Rappl, G, Tilgen, W et al: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583, 2001. (Pubitemid 32112873)
12. Kunz M, Goebeler M, Brocker EB et al: IL-8 mRNA expression in primary malignant melanoma mRNA in situ hybridization: sensitivity, specificity, and evaluation of data. J Pathol 192: 413-415, 2000.
13. Ramjeesingh R, Leung R and Siu CH: Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB J 17: 1292-1294, 2003.
14. Luca M, Huang S, Gershenwald JE et al: Expression of interleukin 8 by human melanoma cells upregulates MMP-2 activity and increased tumor growth and metastasis. Am J Pathol 151: 1105-1113, 1997. (Pubitemid 27424320)
15. Singh RK, Varney ML, Bucana CD et al: Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 9: 383-387, 1999. (Pubitemid 29407071)
16. Brennecke S, Deichman M, Naeher H et al: Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15: 515-522, 2005. (Pubitemid 44124263)
17. Schaider H, Oka M, Bogenrieder T et al: Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 103: 335-343, 2003. (Pubitemid 36076426)
18. Simpson RJ, Hammacher A, Smith DK et al: Interleukin 6: structure-function relationships. Protein Sci 6: 929-955, 1997.
19. Trikha M, Corringham R, Klein B et al: Targeted anti-interleukin 6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003. (Pubitemid 37323267)
20. Yurkovetsky ZR, Kirkwood JM, Edington HD et al: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin Cancer Res 13: 2422-2428, 2007. (Pubitemid 46698593)
21. Tartour E, Dovral T, Mosseri V et al: Serum Interleukin 6 and c-reactive protein levels correlate with the resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 69: 911-913, 1994. (Pubitemid 24140673)
22. Mouawad R, Rixe O, Meric JB et al: Serum Interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Moll Ther 7: 151-156, 2002. (Pubitemid 37531603)
23. Soubrane C, Rixe O, Meric JB et al: Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy. a retrospective study. Melanoma Res 15: 199-204, 2005. (Pubitemid 40839468)
24. Von Felbert V, Córdoba F, Weissenberger J et al: Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 166: 831-841, 2005. (Pubitemid 40315640)
25. Lu C and Kerbel RS: Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288, 1993. (Pubitemid 23064182)
26. Lu C, Vickers MF and Kerbel RS: Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89: 9215-9219, 1992.
27. Haak-Frendscho M, Darvas Zs, Hegyesi H et al: Histidine decarboxylase expression in human melanoma. J Invest Dermatol 115: 345-352, 2000. (Pubitemid 30695754)
28. Darvas Zs, Sakurai E, Hegyesi H et al: Turnover of histamine in human melanoma cell lines. Inflamm Res 49: S70-S71, 2000. (Pubitemid 30262702)
29. Reynolds JL, Akhter J and Morris DL: In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. Melanoma Res 6: 95-99, 1996.
30. Lazar-Molnar E, Hegyesi H, Pallinger E et al: Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur J Clin Invest 32: 743-749, 2002. (Pubitemid 35334969)
31. Molnar EL, Hegyesi H, Toth S et al: Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. Semin Cancer Biol 10: 25-28, 2000. (Pubitemid 30391953)